^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

ANXA11 (Annexin A11)

i
Other names: ANXA11, Annexin A11, Calcyclin-Associated Annexin 50, 56 KDa Autoantigen, Annexin XI, Annexin-11, CAP-50, ANX11, Epididymis Secretory Sperm Binding Protein, ALS23, CAP50
2ms
Physiological and pathological roles of ANXA11: a multifunctional regulator in neurodegeneration and other disorders. (PubMed, Cell Commun Signal)
In this review, we comprehensively explored the physiological and pathological roles of ANXA11 in neurodegeneration and other disorders, with a focus on LLPS, membrane dynamics, and amyloidogenesis. We discussed potential therapeutic strategies targeting the unique properties of ANXA11 and proposed several critical scientific questions that need to be explored.
Review • Journal
|
TARDBP (TAR DNA Binding Protein) • ANXA1 (Annexin A1) • ANXA11 (Annexin A11)
3ms
Potential biomarkers in early detection of gastric cancer. (PubMed, Front Pharmacol)
Thus, the aim of this review is to gather and incorporate the current state of knowledge on this topic to point out the need for persistent research and innovation in the field of identification of GC biomarkers. This will enable the opportunity for new and more effective strategies for combating GC, which will further reduce its global burden and improve patient survival.
Review • Journal
|
SERPINH1 (Serpin family H member 1) • NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) • ANXA1 (Annexin A1) • FAP (Fibroblast activation protein, alpha) • AGT (Angiotensinogen) • ANXA11 (Annexin A11) • CDC42 (Cell Division Cycle 42) • HSPA6 (Heat Shock Protein Family A (Hsp70) Member 6)
5ms
Identification of Colorectal Cancer-Associated Protein Signatures in Small Extracellular Vesicles Based on Proteomics. (PubMed, J Proteome Res)
A logistic regression model combining the five available sEV proteins and two conventional markers demonstrated 78.26% sensitivity and 96.67% specificity for early detection (AUC = 0.961). Our findings nominate these sEV protein signatures as promising noninvasive biomarkers for CRC diagnosis.
Journal
|
ANXA1 (Annexin A1) • CALR (Calreticulin) • ANXA11 (Annexin A11) • ANXA5 (Annexin A5) • CA 19-9 (Cancer antigen 19-9) • KPNB1 (Karyopherin subunit beta-1)
8ms
Correlation between magnetic resonance imaging and definitive histological response in adenocarcinoma of middle and low rectum after neoadjuvant treatment. (PubMed, J Visc Surg)
In conclusion, this analysis reveals 63% concordance between mrTRG and pTRG. Moreover, MRI has a NPV of 81% and therefore MRI is more accurate with poor tumor regression. Thus, mrTRG must be used in association with other clinical or endoscopic outcomes to assess a rectal preservation strategy.
Journal
|
ANXA11 (Annexin A11)
9ms
IgG4-Related Disease: Current and Future Insights into Pathological Diagnosis. (PubMed, Int J Mol Sci)
While histopathology remains the diagnostic cornerstone, a multidisciplinary approach integrating clinical, radiological, and laboratory data is vital. Innovations in biomarkers promise improved diagnostic accuracy and personalized care, balancing novel advancements with foundational pathological evaluation.
Review • Journal
|
ANXA1 (Annexin A1) • ANXA11 (Annexin A11)
10ms
IgG4-Related Cholangitis. (PubMed, Semin Liver Dis)
The diagnosis of IRC is made according to HISORt criteria comprising histopathology, imaging, serology, other organ manifestations, and response to therapy. Treatment of IRC aiming to prevent organ failure and improve symptoms includes remission induction with highly effective glucocorticosteroids and long-term maintenance of remission with immunomodulators such as glucocorticosteroid sparing additives or B cell depleting approaches.
Journal
|
ANXA1 (Annexin A1) • ANXA11 (Annexin A11)
over1year
Non-canonical RNA-binding protein ANXA11 regulates microRNA resorting into small extracellular vesicles to mediate cisplatin resistance. (PubMed, FASEB J)
Taken together, ANXA11 mediates cisplatin resistance through sEV miRNA resorting. Mechanically, ANXA11 binds to miR-148a-3p in a sequence-specific manner to regulate its resorting and thus influences tumor proliferation and chemoresistance.
Journal
|
ANXA1 (Annexin A1) • ANXA11 (Annexin A11) • MIR148A (MicroRNA 148a)
|
ANXA1 overexpression • ANXA1 expression
|
cisplatin
over1year
'Folfirinox' chemotherapy combined with contact x-ray brachytherapy 50kVp and 'CAP50' chemoradiotherapy aiming at organ preservation for selected intermediate distal-middle cT2-T3 rectal cancers: A feasibility study. (PubMed, Cancer Radiother)
The preliminary results of this feasibility study show that early tolerance of these intensive total neoadjuvant treatment is compatible with an acceptable toxicity. The high rate of organ preservation in this intermediate group of T2-T3 tumours is encouraging and is a good argument to start the next randomized TRESOR trial that will aim at achieving a 65% of 3-year survival with organ preservation in this intermediate tumour group.
Journal
|
ANXA11 (Annexin A11)
|
capecitabine • oxaliplatin • irinotecan
over2years
CD38 Is a Functional Partner of CD9 in B-Cell Precursor Acute Lymphoblastic Leukemia (ASH 2023)
This work presents the composition of the CD9 protein web in BCP-ALL, revealing homogenous and heterogeneous partners across the leukemia subtypes. We also provide definitive evidence showing that CD9 binds to and regulates CD38 activity to mediate leukemia progression, representing the first universal protein partner being identified to have a functional consequence in BCP-ALL, thereby providing a mechanistic basis to support the development of CD9-targeted therapies for this life-threatening malignancy.
IO biomarker
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • KMT2A (Lysine Methyltransferase 2A) • AFF1 (AF4/FMR2 Family Member 1) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1) • ANXA1 (Annexin A1) • CD9 (CD9 Molecule) • ANXA11 (Annexin A11) • ADAM10 (ADAM Metallopeptidase Domain 10) • CD81 (CD81 Molecule)
|
CD9 expression
over2years
Biomarkers of ocular allergy and dry eye disease. (PubMed, Rom J Ophthalmol)
The article provides an up-to-date review of the various ocular surface biomarkers that have been identified in DED, OA, or both conditions. Abbreviations: DED = dry eye disease, OA = ocular allergy, SS = Sjogren syndrome, TBUT = tear break up time, TFO = tear film osmolarity, AKC = Atopic keratoconjunctivitis, ANXA1 = Annexin 1, ANXA11 = Annexin 11, CALT = Conjunctival associated lymphoid tissue, CCL2/MIP-1 = Chemokine (C-C motif) ligand2/Monocyte chemoattractant protein 1, CCL3/MIP-1α = Chemokine (C-C motif) ligand 3/Macrophage inflammatory protein 1 alpha, CCL4/MIP-1β = Chemokine (C-C motif) ligand 4/Macrophage inflammatory protein 1 beta, CCL5/RANTES = Chemokine (C-C motif) ligand 5 /Regulated on Activation, Normal T cell Expressed and Secreted, CCR2 = Chemokine (C-C motif) receptor 2, CCR5 = Chemokine (C-C motif) receptor 5, CD3+ = Cluster of differentiation 3 positive, CD4+ = Cluster of differentiation 4 positive, CD8+ = Cluster of differentiation 8 positive, CGRP = Calcitonin-gene-related peptide, CX3CL1 C-X3 = C motif -chemokine ligand 1 /Fractalkine, CXCL8 = Chemokine (C-X-C motif) ligand 8, CXCL9 = Chemokine (C-X-C motif) ligand 9, CXCL10 = Chemokine (C-X-C motif) ligand 10, CXCL11 = Chemokine (C-X-C motif) ligand 11, CXCL12 = Chemokine (C-X-C motif) ligand 12, CXCR4 = Chemokine (C-X-C motif) receptor 4, EGF = Epidermal growth factor, HLA-DR = Human leukocyte antigen-D-related, ICAM-1 = Intercellular adhesion molecule 1, IFN-γ = Interferon-gamma, IgG = Immunoglobulin G, IgE = Immunoglobulin E, IL-1 = Interleukin-1, IL-1α = Interleukin-1 alpha, IL-1β = Interleukin-1 beta, CGRP = Calcitonin-Gene-Related Peptide, IL-3 = Interleukin-3, IL-4 = Interleukin-4, IL-6 = Interleukin-6, IL-8 = Interleukin-8, IL-10 = Interleukin-10, IL-17 = Interleukin-17, IL-17A = Interleukin-17A, LPRR3 = Lacrimal proline-rich protein 3, LPRR4 = Lacrimal proline-rich protein 4, MUC5AC = Mucin 5 subtype AC, oligomeric mucus/gel-forming, MUC16 = Mucin 16, OCT = Optical coherence tomography, OGVHD = Ocular graft versus host disease, PAX6 = Paired-box protein 6, VKC = Vernal keratoconjunctivitis, TGF-β = Transforming growth factor β, S100 = proteins Calcium activated signaling proteins, Th1 = T helper 1 cell, Th17 = T helper 17 cell, MGD = Meibomian gland dysfunction, TFOS = Tear film and ocular surface society, SS-KCS = Keratoconjunctivitis Sicca, MMP-9 = Matrix metalloproteinase 9, MMP-1 = Matrix metalloproteinase 1, ZAG = Zinc alpha glycoprotein, CBA = Cytometric bead array, MALDI TOF-MS = matrix assisted laser desorption ionization-time of flight, SELDI TOF-MS = surface-enhanced laser desorption ionization-time of flight, IVCM = in vivo confocal microscopy, AS-OCT = anterior segment optical coherence tomography, iTRAQ = Isobaric tags for relative and absolute quantitation, LC-MS = Liquid chromatography-mass spectrometry, LCN-1 = lipocalin 1, PIP = prolactin induced protein, NGF = Nerve growth factor, PRR4 = proline rich protein 4, VIP = Vasoactive intestinal peptide, ELISA = enzyme linked immunoassay, TNF-α = tumor necrosis factor alpha, PAC = perennial allergic conjunctivitis, SAC = seasonal allergic conjunctivitis, IC = impression cytology, RT-PCR = reverse transcription polymerase chain reaction, PCR = polymerase chain reaction, APCs = antigen-presenting cells, NK cells = natural killer cells, HEL = hexanoyl-lysine, 4-HNE = 4-hydroxy-2-nonenal, MDA = malondialdehyde.
Journal
|
CD8 (cluster of differentiation 8) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • MUC16 (Mucin 16, Cell Surface Associated) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD4 (CD4 Molecule) • ICAM1 (Intercellular adhesion molecule 1) • IL10 (Interleukin 10) • CCL4 (Chemokine (C-C motif) ligand 4) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • ANXA1 (Annexin A1) • CCL2 (Chemokine (C-C motif) ligand 2) • EGF (Epidermal growth factor) • TGFB1 (Transforming Growth Factor Beta 1) • IL17A (Interleukin 17A) • IL1A (Interleukin 1, alpha) • MMP9 (Matrix metallopeptidase 9) • ANXA11 (Annexin A11) • CCL3 (C-C Motif Chemokine Ligand 3) • CCR2 (C-C Motif Chemokine Receptor 2) • CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4) • MMP1 (Matrix metallopeptidase 1) • MUC5AC (Mucin 5AC)
over2years
IgG4-related cholangitis - a mimicker of fibrosing and malignant cholangiopathies. (PubMed, J Hepatol)
For remission induction glucocorticosteroids are highly effective, after which immunomodulators can be introduced for maintenance of remission as glucocorticosteroid sparing alternatives. Increased insight into the pathogenesis of IRC will lead to improved diagnosis and novel therapeutic strategies in the future.
Review • Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • ANXA1 (Annexin A1) • ANXA11 (Annexin A11) • SLAMF7 (SLAM Family Member 7)
over3years
Urine proteomic signatures predicting the progression from premalignancy to malignant gastric cancer. (PubMed, EBioMedicine)
This study revealed distinct urine proteomic profiles and a panel of proteins that may predict the progression of gastric lesions and risk of GC. These biomarkers in a non-invasive approach may have translational significance for defining high-risk populations of GC and its early detection.
Journal
|
ANXA1 (Annexin A1) • ANXA11 (Annexin A11) • CDC42 (Cell Division Cycle 42)